EN | TR
E-ISSN: 3061-9947
A Comparison of the BEAM and BuCyE Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma: A Single-Center Experience
PDF
Cite
Share
Request
Original Article
VOLUME: 54 ISSUE: 3
P: 291-297
2021

A Comparison of the BEAM and BuCyE Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma: A Single-Center Experience

Acta Haematol Oncol Turc 2021;54(3):291-297
DOI: 10.5505/aot.2021.81084
Hikmettullah Batgi 1
Semih Başcı 1
Samet Yaman 1
Bahar Uncu Ulu 1
Tuğçe Nur Yiğenoğlu 1
Mehmet Sinan Dal 1
Merih Kızıl Çakar 1
Fevzi Altuntaş 1
1. Department Of Hematology And Bone Marrow Transplantation Center, Dr. Abdurrahman Yurtaslan Ankara Oncology Training And Research Hospital
2.
No information available.
No information available
Received Date: 2021-01-10T13:50:12
Accepted Date: 2021-12-01T07:05:10
PDF
Cite
Share
Request

Abstract

INTRODUCTION

High-dose chemotherapy applied together with autologous stem cell transplantation (ASCT) is a commonly used treatment modality in patients with relapsed/refractory Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL). The aim of this study was to investigate the efficacy and toxicity of BuCyE (busulfan, cyclophosphamide, and etoposide) and BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimens in patients with relapsed/refractory lymphoma scheduled for ASCT.

METHODS

Between December 2018 and November 2019, 24 patients with relapsed or refractory HL (n = 16) and NHL (n = 8) who underwent ASCT following BEAM (n=12) and BuCyE (n=12) preparative regimens were analyzed retrospectively at Bone Marrow Transplantation Unit of Abdurrahman Yurtaslan Ankara Oncology Training and Research. The groups were compared in terms of patient characteristics, hematopoietic engraftment time, toxicity profiles, and progression free survival (PFS).

RESULTS

No significant differences were detected between the groups with regard to age, gender distribution, ecog, sorror score, diagnosis, pre-ASCT stage (early/late), chemotherapy line, pre-ASCT response and pre-ASCT radiotherapy(p > 0.05). The median number of infused CD34+ cells/kg, neutrophil and platelet engraftment statuses, duration of hospitalization, need for erythrocyte and platelet transfusion of BuCyE and BEAM groups were found to be similar (p > 0.05). More patients in the BuCyE group developed mucositis and febrile neutropenia, but this difference was not statistically significant (p > 0.05). At a median follow-up of 13 months(1–21 months) after ASCT, the median PFS could not be reached. No difference was found in PFS between regimes(p = 0.68).

DISCUSSION AND CONCLUSION

BuCyE followed by ASCT is an effective conditioning regimen in relapsed/refractory lymphoma patients. This regimen may be an important treatment option as a substitute for carmustine containing regimens. However, in the absence of prospective trials, it is difficult to suggest a conditioning regimen due to the low level of evidence. It is important to participate in ongoing clinical trials.